Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #10 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Lupin Limited (this stock) | 91,949 | 13.2 | 23.8% | 3.8% | — | 92 | 75 | 44 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 8,277 | 2,017 | 1,417 | ₹ |
| March 31, 2026 | 7,475 | 1,928 | 1,469 | ₹ |
| Dec. 31, 2025 | 7,168 | 1,522 | 1,181 | ₹ |
| Sept. 30, 2025 | 7,048 | 2,007 | 1,485 | ₹ |
| June 30, 2025 | 6,268 | 1,416 | 1,221 | ₹ |
| March 31, 2025 | 5,667 | 896 | 782 | ₹ |
| Dec. 31, 2024 | 5,768 | 1,071 | 859 | ₹ |
| Sept. 30, 2024 | 5,673 | 1,055 | 859 | ₹ |
| June 30, 2024 | 5,600 | 993 | 806 | ₹ |
| March 31, 2024 | 4,961 | 498 | 368 | ₹ |
| Dec. 31, 2023 | 5,197 | 736 | 619 | ₹ |
| Sept. 30, 2023 | 5,039 | 630 | 495 | ₹ |
| June 30, 2023 | 4,814 | 559 | 453 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 27,958 | 6,873 | 5,355 |
| March 31, 2025 | 22,708 | 4,015 | 3,306 |
| March 31, 2024 | 20,011 | 2,422 | 1,936 |
| March 31, 2023 | 16,642 | 716 | 448 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 7,546 | -4,076 | -846 | 2,055 | 5,491 |
| March 31, 2025 | 430 | -1,602 | 1,732 | 1,682 | -1,252 |
| March 31, 2024 | 3,490 | -1,554 | -2,184 | 929 | 2,562 |
| March 31, 2023 | 1,934 | -1,324 | -337 | 1,500 | 434 |
| March 31, 2022 | 1,082 | 577 | -1,572 | 905 | 177 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 38,365 | 22,513 | 22,357 | 4,267 | 1,643 | 24,027 | 12,651 | 4,168 | 5,449 | 6,083 |
| March 31, 2025 | 29,205 | 17,294 | 17,112 | 3,310 | 1,766 | 16,799 | 8,961 | 1,544 | 5,148 | 5,476 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
